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Abstract
Background: Developmental dysplasia of the hip (DDH) is a common pathological condition of the
musculoskeletal system in infants which results in a congenital and developmental malformation of the hip joint.
DDH is a spectrum of pathologies affecting the infant hip ranging from asymptomatic subtle radiographic signs
through mild instability to frank dislocations with acetabular dysplasia. A Saudi family with three affected individuals
with DDH was identified and genetic analysis was performed to detect the possible genetic defect(s) underlying
DDH in the affected members of the family.
Methods: We performed whole genome genotyping using Illumina HumanOmni 2.5 M array and whole exome
sequencing (WES) using Nextera Rapid capture kit and Illumina NextSeq500 instrument in four individuals of a
family with DDH.
Results: SNP data analysis did not identify any runs of homozygosity and copy number variations. Identity-by-
descent (IBD) analysis on whole genome genotyping data identified a shared haplotypes on chromosome 1 in
affected individuals. An analysis of the WES data identified rare heterozygous variants in HSPG2 and ATP2B4 genes in
the affected individuals. Multiple prediction software predicted that the variants identified are damaging. Moreover,
in silico analysis showed that HSPG2 regulates ATP2B4 expression using a variety of transcription factors.
Conclusion: Our results indicate that there might be a functional epistatic interaction between HSPG2 and ATP2B4,
and DDH in the family studied is due to a combined effect of both variants. These variants are also present in the
asymptomatic mother suggesting that the variants in HSPG2 and ATP2B4 are incompletely penetrant. This study
provides the first evidence of digenic inheritance of DDH in a family and extends the spectrum of genetic
heterogeneity in this human disorder.
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Background
Developmental dysplasia of the hip (DDH; MIM 142700)
is a developmental disorder of the hip joint that results
in an abnormal socket of the femoral head, ranging from
instability, subluxation and complete dislocation of the
hip joint, reduced joint function, and accelerated wear of
the articular surface, which may result in early arthritis
[1, 2]. Phenotypic variability has been observed in indi-
viduals affected with DDH.
The etiology of DDH is multifactorial, involving both
genetic and environmental risk factors. Non-genetic risk
factors include breech presentation, oligohydramnios, and
primiparity [3]. Families with members affected with DDH
has been reported [4–8]. This provides supports to the
argument that DDH has a strong genetic basis [9–12].
Linkage analysis, exome sequencing and case-control as-
sociation studies have so far identified several loci/genes
associated with DDH [13]. Although, DDH is observed as
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an isolated condition in majority of patients with unilat-
eral or bilateral hip involvement, it can be associated with
other conditions such as clubfeet, renal malformations
and cardiac anomalies [14].
An incidence of 1.5 - 20 cases of DDH per 1000 live
births has been described [15]. Though, in some countries
including Italy, Japan and other Mediterranean countries
the prevalence of DDH is higher [16]. The variations in in-
cidence rate is due to differences in diagnostic methods and
the timing of evaluation of DDH affected individuals [17].
In the Middle East, few hospital based studies have shown
an incidence rate of 3.17 - 3.50 per 1000 live births [18–20].
Genetic risk factors for DDH have mainly been searched
for through case-control studies which have identified
several candidate genes associated with bone and joint biol-
ogy [4, 6, 8, 20–24]. These includes GDF5, TBX4, ASPN,
TGFB1 and IL6 genes. However, no firm genotype-
phenotype relations have been established for DDH yet.
Linkage analysis based on whole genome genotyping data
has detected several chromosomal loci linked with DDH
phenotype in extended pedigrees [6, 8, 20]. However, until
now, studies presenting results from genetic analysis of
such large families segregating DDH are very limited. So
far, only two genes of interest were identified from such
analyses. Feldman et al [2] identified a variant in CX3CR1
shared by all DDH affected members of a 4-generational
family. More recently, a mutation in the gene UFSP2 was
found to follow an autosomal dominant inheritance pattern
with reduced penetrance (estimated at 80%) in a family
from South-Africa with Buekes hip dysplasia [25].
The paucity of genetic information on DDH patients
from Middle East emphasizes the need for comprehensive
genomic studies to identify the candidate gene(s) in this
population. We performed whole genome single nucleotide
polymorphism (SNP) genotyping and whole exome
sequencing (WES) in a Saudi family with three individuals
showing DDH. We identified probably pathogenic hetero-
zygous variants in HSPG2 and ATP2B4 genes in the af-
fected individuals. Our data showed that the genetic
variants underlying DDH are not completely penetrant.
Methods
Genetic analysis of 5 individuals (III:3, III:4, III:5, IV:1, IV:2)
including 3 affected members (III:5, IV:1, IV:2) in a single
family of Saudi origin (Fig. 1a) showing an isolated form of
DDH was carried out. All affected individuals in the family
were clinically and radiologically examined by a Pediatric
Orthopedic Surgeon. Permission to undertake the study
was obtained from the Research Ethics Committee (REC)
of Taibah University. An informed consent for genetic
evaluation was obtained from all participants. The blood
samples from 5 individuals were obtained in EDTA tubes.
Genomic DNA was isolated using QIAamp DNA mini kit.
Concentration and quality of DNA was assessed by
Nanodrop spectrophotometer (Green BioResearch, Baton
Rouge, LA 70808, USA) and Qubit fluorometer (Thermo-
Fisher Scientific Inc).
Sanger Sequencing of Known Genes Associated with DDH
The family members were first tested for mutations in the
known genes previously associated with DDH. The genes
sequenced included asporin (ASPN) at chromosome
9q22.31, chemokine receptor 1 (CX3CR1) at chromosome
3p22.2, dickkopf WNT signaling pathway inhibitor 1
(DKK1) at chromosome 10q21.2, growth differentiation fac-
tor 5 (GDF5) at chromosome 20q11.22, homeobox B9
(HOXB9) at chromosome 17q21.32, homeobox D9
(HOXD9) at chromosome 2q31.1, pappalysin 2 (PAPPA2)
Fig. 1 Pedigree drawings of the family with Developmental Dysplasia of the Hip (DDH). Open squares and circles represent unaffected males and
females, respectively. Filled squares and circles represent affected individuals. Double lines between symbols are representative of consanguineous
unions. +/+ indicate wild type homozygote, while +/- indicate heterozygotes (a). Anterio-posterior radiographs of the pelvis of an affected individual
(IV:2) showing bilateral hip dislocation with bilateral acetabular dysplasia (b)
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at chromosome 1q25.2, and transforming growth factor,
beta 1 (TGFB1) at chromosome 19q13.2.
Whole genome SNP genotyping
Illumina HumanOmni 2.5 M SNP array was used for whole
genome SNP genotyping. A total of 200 ng genomic DNA
from four members (III:3, III:4, III:5, IV:2) of a family was
used as a starting material. Briefly, 0.1 N NaOH was used
for DNA denaturation and whole genome was amplified
out with Random Primers Mix (RPM) using Multi Sample
Master Mix (MSM). Enzymatic fragmentation of the ampli-
fied DNA was carried out using Fragmentation Mix (FMS)
followed by precipitation using Precipitation Mix 1 (PM1)
and 2-propanol. Fragmented DNA was hybridized to Bead-
Chip by denaturing the sample and dispensing 35 ul of the
sample onto the BeadChip section followed by incubation
for 18 hours at 48 °C in the hybridization oven. Single base
extension on BeadChips was performed after washing and
staining. Single base extension reaction incorporates labeled
nucleotides into the extended primers. Scanning of
BeadChips was performed in Illumina iScan using iScan
control software. Illumina GenomeStudio software and
HomozygosityMapper were used to call loss of hetero-
zygous (LOH) regions while the Illumina Genome
Viewer incorporated in GenomeStudio was used to de-
tect copy number variations (CNVs) in the genome.
Identity-by-descent (IBD) analysis was carried out using
PLINK [26] to identify shared genomic regions.
Whole exome sequencing (WES)
Four individuals (III:3, III:4, III:5, IV:2) were initially avail-
able for exome sequencing. Nextera Rapid Capture Exome
kit was used for library preparation and exome enrichment.
This kit captures 214,405 exons and splice site and covers
98.3% RefSeq. Cluster generation and DNA sequencing was
performed on Illumina NextSeq500 instrument.
Briefly, 50 ng of DNA was fragmented enzymatically and
tagged with adaptor sequences (tagmentation) followed by
purification and amplification of the purified tagmented
DNA. Resulting libraries were purified with magnetic beads
and target regions were captured with whole exome oligos
followed by PCR amplification of the enriched library.
Quantification of enriched library was performed with
Qubit fluorometer and library size distribution was mea-
sured with Agilent Bioanalyzer. Quantified DNA library was
loaded on flow cell for subsequent cluster generation and
sequencing was carried out with an Illumina NextSeq500
instrument. NextSeq500 generates bcl files for each of the
four lanes. These files were converted to fastq files using
BCL2FASTQ tool. BWA aligner incorporated in BaseSpace
was used to align fastq files to the reference genome using
the BWA-MEM algorithm. Variants were called using gen-
ome analysis tool kit (GATK). Illumina VariantStudio was
used for annotation and filtration of the genomic variants
(Additional file 1: Figure S1). Loss of heterozygosity (LOH)
analysis was performed on exome data of individuals III:5
and IV:2.
Sanger sequencing was performed for variants of inter-
est to confirm the variants discovered by WES. Genomic
sequences of the HSPG2 and ATP2B4 genes, including
exons, introns, 5′ untranslated region and 3′ untrans-
lated region, were retrieved from the Ensembl genome
browser (http://asia.ensembl.org/index.html). Primer-3
software (http://frodo.wi.mit.edu/primer3/) was used to
design primers for PCR amplification of the variants and
their flanking regions. BIOEDIT sequence alignment edi-
tor version 6.0.7 (Ibis Biosciences Inc., Carlsbad, CA,
USA) was used for sequence alignment.
Sanger reads for known genes sequenced in this study,
whole genome SNP genotypes and exome variant files
are available upon request.
Results
Clinical description of patients
The manifestation of DDH is bilateral hip dislocation in
both affected individuals. Proband (IV:2) is a 2 year old
female with bilateral DDH, discovered after watching
her gait during walking. Her pelvic radiograph showed
bilateral hip dislocation with bilateral acetabular dyspla-
sia (Fig. 1b). She was treated by staged bilateral open hip
reduction and pelvic osteotomy.
Her 30 years old maternal uncle (III:5) was presented
with the same phenotypic manifestation. A third affected
individual (IV:1) was identified while interviewing elders
of the family. All affected individuals are of normal stat-
ure and have no other associated abnormality.
Whole genome genotyping data analysis
Sequencing data analysis of the known genes (ASPN,
CX3CR1, DKK1, GDF5, HOXB9, HOXD9, PAPPA2,
TGFB1) excluded their involvement in causing DDH in
the present family.
After excluding known genes, whole genome homozygos-
ity mapping was carried out using Illumina 2.5 M BeadChip
array. SNP genotypes were called by the BRLMM algorithm
incorporated in Illumina GenomeStudio genotyping mod-
ule. A call rate of more than 99% was obtained across the
entire sample. Mapping order and physical and genetic
distances of SNPs were obtained from Illumina. Analysis of
SNP data to detect LOH was conducted using GenomeStu-
dio software, HomozygosityMapper and AutoSNPa. How-
ever, no shared blocks of homozygosity were found in
affected individuals. Moreover, Genome Viewer failed to
find any shared pathogenic CNVs in the affected individ-
uals. In order to identify genomic regions that are shared
between affected individuals, genotyping data was subjected
to IBD analysis using PLINK [26]. A shared haplotypes
were detected on chromosome 1 in all 3 affected
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individuals (Fig. 2). The percentage of homozygosity ranged
from 7-29% based on regions of homozygosity >10 Mb.
Whole exome sequencing (WES) data analysis
WES was performed in the four individuals including the
two affected (III:5, IV:2) and the two asymptomatic mem-
bers (III:3, III:4) of the family. Average coverage achieved
was between 65-92% (Table 1 and Table 2). The resulting
variant call format (VCF) files contains on average 80,000
variants. These variants were filtered based on quality,
frequency, genomic position, protein effect, pathogenicity
and previous associations with the phenotype (Additional
file 2: Figure S2).
LOH analysis was performed on exome data of individ-
uals III:5 and IV:2. However, no shared blocks of homozy-
gosity were detected for these samples. In a first approach
to find possible relevant variants in the affected members
of this family, we looked for the previously reported
variants in the CX3CR1 and UFSP2 genes; and then ex-
panded the search for other potential candidate variants
in the same genes. However, the described variants were
not present in any of the family members nor any other
candidate variants were found in these genes. Further-
more, WES reads for already known genes including
ASPN, CX3CR1, DKK1, GDF5, HOXB9, HOXD9, PAPPA2,
TGFB1 were aligned and inspected manually for any
Fig. 2 Haplotypes obtained from PLINK based IBD analysis using SNP genotyping data. All three affected individuals share haplotype carrying the
mutant allele. Green color is used for HSPG2 flanking haplotypes while blue color is used for ATP2B4 flanking haplotypes
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deletion or duplication in these genes. No deletion or
duplication in known genes were found.
In a second approach of finding candidate variants in
the family, the exome data of the affected and the un-
affected members were analyzed simultaneously. The
pedigree was analyzed to establish the most likely inher-
itance pattern for a shared genetic cause of DDH in the
family. De novo occurrence of candidate variants was
not considered given the multiple affected family mem-
bers with similar phenotypes and hence an expected
shared genetic cause. X-linked inheritance was consid-
ered unlikely as there is an affected female in the family.
An autosomal recessive inheritance could not be ex-
cluded based on the pedigree. However, homozygosity of
a causal variant and compound heterozygosity in both
affected family members, cannot be excluded.
Different filter settings were applied to look for potential
candidate variants under an autosomal recessive inherit-
ance model. More specifically, the analysis looked for (1)
candidate variants present in homozygous state in IV:2, in
heterozygous state in III:4, and present in homozygous or
heterozygous state in III:5 [assuming at least a partially
shared genetic cause of DDH in both affected members],
(2) candidate variants present in homozygous state in III:5,
in heterozygous state in III:4, and present in homozygous
or heterozygous state in IV:2 [assuming at least a partially
shared genetic cause of DDH in both affected members]
and (3) candidate variants present in compound heterozy-
gous state in IV:2, of which one variant is present in hetero-
zygous state in both III:4 and III:5. In addition, another rare
variant in the same gene would then be expected to be
present in III:5. However, in accordance with the listed
criteria here for an autosomal recessive model, no candi-
date variants were found.
Finally, an autosomal dominant inheritance with
incomplete penetrance was considered. Interestingly,
this inheritance pattern has been suggested in scientific
literature for familial forms of DDH and is a valid option
based on the pedigree. Under this model, individual III:4
(unaffected mother) would be expected to be an asymp-
tomatic carrier of the candidate variant, and the affected
individuals III:5 and IV:2 would be expected to both
carry this candidate variant.
Similar to the family analysis performed by Feldman et
al. [2], only rare variants were taken into account (allele
frequencies below or equal to 1% in 1000G, ExAC and
our in-house database of Saudi variants), and only vari-
ants located within genes (exonic and intronic) or pro-
moter regions were considered. Furthermore, some
quality parameters were taken into account including
the depth of coverage (DP > 10) in at least 1 family
member, the absence of allelic imbalance in at least 1
family member and good genotype quality (GQ > 20) in
at least 1 family member.
Of the variants that came out of this filtering proced-
ure, 59 were not present in dbSNP and were, as such,
considered as 'new' variants. Genes in which these 59
variants are located are listed in Panel 1 and in supple-
mentary table. Out of 59 variants, variants in 57 genes
were present in all family members with no link to hip
dysplasia. Only 2 genes (HSPG2 and ATP2B4) were
found to be linked to hip dysplasia or other skeletal or
bone/joint abnormalities. The variants in these genes in-
clude heterozygous rare coding variants in the HSPG2
(c.3328G > T) and ATP2B4 (c.2264G > A) genes.
Sanger validation
The 59 variants were Sanger sequenced in all three af-
fected individuals (III-5, IV-1, IV-2) and parents (III-3, III-
4). All three affected individuals shared variants in HSPG2
and ATP2B4 genes only. The entire relevant coding exons
of the HSPG2 and ATP2B4 genes were subsequently
Table 1 Pre-alignment statistics
Sample ID Total Read
Bases (bp)




III-3 11,149,473,250 84,775,682 131.52 44.7 78.0 64.3 95.6 65.0
III-4 15,035,517,174 107,770,286 139.51 44.0 77.6 63.6 95.8 79.2
III-5 15,498,839,720 113,685,720 136.33 44.1 81.2 68.0 96.7 92.8
IV-2 12,988,837,852 97,813,060 132.79 44.5 78.0 64.2 95.6 72.7





















III-3 48,829 9,692 8,542 67 33 3,208 252 98.3 1.1 2.4
III-4 51,488 9,632 8,457 64 26 3,545 237 98.1 1.0 2.4
III-5 56,735 10,333 9,066 79 25 4,959 267 97.7 1.2 2.4
IV-2 50,994 9,826 8,712 46 28 3,343 174 98.2 1.1 2.4
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sequenced in all affected and unaffected subjects of the
family. Variants identified through WES were also de-
tected by Sanger sequencing (Fig. 3). A third affected indi-
vidual (IV:1) was also screened using Sanger sequencing
and was found positive for variants detected by exome
sequencing.
In silico analysis
Variants in HSPG2 and ATP2B4 occur at highly conserved
residues (Table 3) and are predicted to be deleterious by
the majority of bioinformatics results (Table 4). Moreover,
I-Mutant software (used for prediction of protein stability
upon single point mutation) predicted the mutant protein
Fig. 3 Sequence chromatograms of heterozygous variants identified in all three individuals of a family segregating DDH. The upper panel (a)
represents the nucleotide sequences in all affected individuals in HSPG2 (c.3328G > T) gene and the lower panel (c) represents the nucleotide
sequences in all affected individuals in ATP2B4 (c.2264G > A) gene. Panel b and d shows partial nucleotide sequence of the control individuals for
HSPG2 and ATP2B4. Arrow head indicates the variant site
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as less stable [27]. Furthermore, we used DUET (predict-
ing effects of mutations on protein stability via an inte-
grated computational approach), SDM (predicting effects
of mutations on protein stability and malfunction) and
mCSM (predicting the effect of mutation in protein using
graph based signatures) for prediction of effect of muta-
tion on the protein and found that these variants are in-
deed destabilizing [28–30]. Pathway commons network
visualizer (PCViz) was used to detect interaction between
HSPG2 and ATP2B4 protein [31]. No direct interaction
between these two proteins was detected. However,
HSPG2 indirectly controls expression of ATP2B4 via var-
iety of transcription and regulatory factors including
GATA1, MAZ and RFX1 (Fig. 4).
Discussion
Exome variants were filtered considering an autosomal
dominant inheritance with incomplete penetrance. Inter-
estingly, this inheritance pattern has been suggested in
scientific literature for familial forms of DDH and is a
valid option based on the pedigree [2, 7, 25]. This model
explains why the mother (III:4) is an asymptomatic car-
rier of the candidate variant, while the affected individ-
uals IV:2 and III:5 are carrying these candidate variants.
A novel missense variant in HSPG2 was detected in
heterozygous state in both affected family members
(IV:2 and III:5) and in the unaffected mother (III:4) of
IV:2. The unaffected father does not carry this variant.
Similarly, a novel missense variant in ATP2B4 was de-
tected in heterozygous state in the affected family mem-
bers (IV:2 and III:5) and in the unaffected mother (III:4)
of IV:2. The unaffected father does not carry this variant.
Hence, the segregation of these variants is in accordance
with an autosomal dominant inheritance with incom-
plete penetrance.
HSPG2 encodes for the perlecan protein, a multi domain
proteoglycan that cross-links extracellular matrix compo-
nents and cell-surface molecules, which is essential for many
biological activities. It has been shown that perlecan protein
is strongly associated with musculoskeletal development,
both in mouse and in human, making it a potential candi-
date gene for skeletal phenotypes such as DDH [32, 33].
Loss of function mutations in HSPG2 results in a musculo-
skeletal phenotype in both mouse and humans. For instance,
mutations in HSPG2 gene can cause the autosomal recessive
conditions Schwartz-Jampel syndrome type 1 (SJS1) and
Silverman-Handmaker type of dyssegmental dysplasia. SJS1
is an autosomal recessive disease characterized by perman-
ent myotonia and skeletal dysplasia, resulting in reduced
stature, kyphoscoliosis, bowing of the diaphyses and
irregular epiphyses. Other symptoms may include eye ab-
normalities such as cataract, which is also often associated
with myotonic dystrophy [34]. Dyssegmental dysplasia
Silverman-Handmaker type (DDHS) is an autosomal reces-
sive skeletal dysplasia characterized by marked differences in
size and shape of the vertebral bodies (anisospondyly) and
short-limbed dwarfism. There are two recognized types: the
severe, lethal DDSH (or lethal Kniest-like syndrome) and
the milder Rolland-Desbuquois form. Individuals with
DDSH also show flat face, micrognathia, cleft palate and re-
duced joint mobility. Moreover, they have an encephalocoele
[35]. Besides these two Mendelian inherited conditions, a
missense mutation in HSPG2 (p.Asn786Ser) has recently
been linked with idiopathic scoliosis based on exome se-
quencing analysis of a multigenerational family of European
ancestry with familial scoliosis. Interestingly, segregation
Table 3 Multiple sequence alignment for variants in HSPG2
(p. Ala1110Ser) and ATP2B4 (p. Arg755Gln)


















Table 4 Rare heterozygous exome variants [HSPG2 (c.3328G > T; p.Ala1110Ser) and ATP2B4 (c.2264G > A; p.Arg755Gln) identified in
all affected individuals with developmental dysplasia of the hip






CADD GERP++ PhastCons SiPhy Phylop VEST3
HSPG2 Missense 0.0% 0.999 0.01 1.0 2.8 26.2 5.44 0.84 10.23 0.83 0.55
ATP2B4 Missense 0.0% 0.997 0.0 1.0 4.6 35.0 5.2 1.0 18.36 0.95 0.92
a1000 Genome, Exome Aggregation Consortium, 64 exome sequences from Saudi individuals
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analysis in this family also suggested an autosomal dominant
inheritance pattern with incomplete penetrance [36].
The variant detected here causes an alanine to serine
(p.Ala1110Ser) missense substitution within laminin IV
type A2 domain of the protein, which might affect pro-
tein interactions. HSPG2 variation has been linked to
hip dysplasia in both human and mice. Hip dysplasia
can be present in patients with SJS1 [36]. In mice, a spe-
cific mutant HSPG2 strain (C1532Yneo) was described
to have reduced body weight and to develop chondro-
dysplasia and hip dysplasia [37].
ATP2B4, also known as PMCA4, encodes the plasma
membrane calcium-transporting ATPase 4 enzyme, which is
involved in catalyzing the hydrolysis of ATP, coupled with
the transport of Ca2+ out of the cell. PCMA proteins includ-
ing PCMA4 were suggested to play important roles in the
regulation of bone homeostasis in both mice and humans
by modulating calcium signaling in osteoclasts [38].
Mutations in ATP2B4 have only recently been linked
to a disease phenotype. More specifically, a specific
missense mutation (c.803G > A, p.R268Q) was shown to
cause autosomal dominant familial spastic paraplegia in
a Chinese family [39]. Further studies on the detected
mutation revealed functional changes in calcium homeo-
stasis in human neuronal cells, suggesting that calcium
dysregulation may be associated with the phenotype in
that family [40].
The variant detected here causes an arginine to
glutamine (p.Arg755Gln) missense substitution within a
cytoplasmic domain of the ATP2B4 protein.
Based on in silico predictions, the altered residues of
HSPG4 and ATP2B4 are conserved (Table 3), and the
Fig. 4 Pathway commons network visualizer (PCViz) was used to detect interaction between HSPG2 and ATP2B4 protein. No direct interaction
between these two proteins were detected. However, HSPG2 indirectly controls expression of ATP2B4 via variety of transcription and regulatory
factors including GATA1, MAZ and RFX1. Green lines between genes shows control of expression. Genes encoding miRNA are shown in red while
transcription factors are shown in black text
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detected changes are predicted to have functional effects
at the protein level (Table 4).
Conclusions
In conclusion, these variants are reported based on their
rarity in the general population (absent from 1000G, ExAC
and dbSNP), in accordance with an autosomal dominant
inheritance with incomplete penetrance shown by the fam-
ily pedigree and the association of other HSPG2 mutations
with several skeletal phenotypes including hip dysplasia in
human and mice points towards the role of ATP2B4 in
bone formation through modulation of calcium signaling.
A significant enrichment of the detected variants here or
other rare HSPG2 and ATP2B4 variants in independent
cohorts of DDH patients could provide a further evidence
of the role of HSPG4 and ATP2B4 genes in general or the
detected variants here in particular in the DDH phenotype.
Pathway analysis identified indirect interaction be-
tween HSPG2 and ATP2B4 proteins. HSPG2 regulate
the ATP2B4 expression via a variety of transcription fac-
tors including GATA1, RFX1 and MAZ (Fig. 4). The
genotype-phenotype relationship may be the combined
effect of both mutations in each gene. Epistatic relation-
ship between HSPG2 and ATP2B4 genes remain specula-
tive until functional studies are performed.
This study provides the first evidence of a digenic inher-
itance in DDH in a family and extends the spectrum of
genetic heterogeneity in this human DDH. in vitro func-
tional studies are required to understand the mechanism
underlying the role of epistatic interactions in DDH.
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during generation of annotated variant file from raw data. (JPG 83 kb)
Additional file 2: Figure S2. Variant filtration process illustrating the
exome filtering scheme in two affected individuals. Panel 1: Genes
containing rare variants (1% in 1000G/ExAC/in-house database; absent from
dbSNP) and in accordance with an autosomal dominant inheritance with
incomplete penetrance (shared between affected samples III:5 and IV:2).
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